MASHINIi

Neurogene Inc..

NGNE.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Neurogene Inc. is a clinical-stage biotechnology company focused on developing transformative genetic medicines for neurological diseases. The company engineers and develops gene therapy product candidates designed to address the underlying genetic causes of neurological disorders. Their pipeline in...Show More

Ethical Profile

Mixed.

Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare neurological diseases like Rett syndrome and CLN5 Batten disease, directly addressing significant unmet medical needs. This core mission strongly aligns with improving global health. However, the development of these therapies inherently requires preclinical animal testing for regulatory approval, which critics point to as a conflict with animal welfare. Employee sentiment, based on available reviews, appears mixed, with some praising company culture while others allegedly criticize management and communication; an estimated average annual salary of $121,460 has been reported. The company's reliance on complex biotechnologies and sensitive patient data also highlights a high materiality for safe and smart tech practices. Information on ethical sourcing, environmental impact, and fair business conduct remains largely unavailable.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-80
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Neurogene Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

No evidence available to assess Neurogene Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No specific, quantitative data points were provided across the articles for any of the KPIs related to Fair Pay & Worker Respect, such as living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

1
The articles explicitly state that this information is not available or not provided.

Fair Trade & Ethical Sourcing

0

No specific, concrete data points were found in the provided articles to assess Neurogene Inc. against any of the Fair Trade & Ethical Sourcing KPIs. The articles, primarily a proxy statement and a code of business conduct, do not contain information regarding fair-trade certifications, supplier audit frequencies, forced or child labor incidents, supply chain traceability, remediation speed for supplier violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend.

1

Honest & Fair Business

0

No specific, concrete evidence was found in the provided articles to assess Neurogene Inc. against any of the KPIs for the 'Honest & Fair Business' ethical value. The articles contain general corporate and financial information, but no data points relevant to regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification of ethical claims.

1

Kind to Animals

-80

Neurogene Inc. conducts extensive preclinical studies using various animal models, including mice, non-human primates, and dogs, for safety, efficacy, tolerability, toxicity, biodistribution, and pharmacokinetic/pharmacodynamic analyses.

1
There is no evidence of the company employing validated non-animal testing methods to replace these animal tests. The company's animal testing policy is not explicitly stated, but its consistent and extensive use of animal models for preclinical validation and regulatory submissions indicates a reliance on animal testing without clear commitments to reduction or alternatives. While specific numbers of animals used are not provided, the repeated mention of 'extensive' studies across multiple animal types suggests a high volume without transparent reduction targets.
2
There is no evidence of investment in animal-free technologies or participation in collaborations for animal-free R&D. The company engages with regulatory bodies like the FDA but does not show public engagement in animal welfare policy improvement or advocacy for higher standards.
3

No War, No Weapons

0

The provided articles discuss Neurogene Inc.'s gene therapy research and development for neurological diseases, and traffic data for an unrelated company (VINCI). No information is available regarding Neurogene Inc.'s involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other activities relevant to the 'No War, No Weapons' ethical value.

1
Therefore, no KPIs could be assessed.

Planet-Friendly Business

0

The provided articles focus exclusively on Neurogene Inc.'s financial performance, clinical trial progress, and regulatory actions. All articles explicitly state that no information regarding environmental, social, and governance (ESG) metrics or planet-friendly business practices is available.

1
Consequently, no KPIs related to planet-friendly business could be assessed based on the evidence provided.

Respect for Cultures & Communities

0

No specific, concrete data points were found in the provided articles to assess Neurogene Inc. against any of the KPIs for 'Respect for Cultures & Communities'.

1
Both articles explicitly state that no data was found for the company or the ethical value.
2

Safe & Smart Tech

0

No evidence available to assess Neurogene Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

The provided articles, including Neurogene Inc.'s 2023 Form 10-K and a LinkedIn job posting for an EHS role, do not contain specific, quantitative data related to waste management, product recyclability, packaging sustainability, or other circular economy practices. The Form 10-K explicitly notes limited data on sustainability metrics, focusing instead on financial and clinical development.

1
While the job posting mentions responsibilities like overseeing waste management and conducting audits, it provides no performance metrics, initiatives, or specific details relevant to the KPIs.
2

Own Neurogene Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.